source
- Gilead agrees to pay $1.28 billion upfront to China's PepStar for oral IL-23 inflammation drug candidateGilead Sciences announced a deal with Chinese biotech PepStar Therapeutics to acquire an early-stage oral IL-23 inhibitor. The agreement includes an upfront payment of roughly $1.28 billion for Pe…
- BMS reports fatal septic pneumonia in MS patient during CAR T trial of zolacabtagene autoleucelBMS disclosed that a participant in its Phase 1 Breakfree-2 study of the CAR T cell therapy zolacabtagene autoleucel died from septic pneumonia. The patient, who had highly active relapsing multip…